Skip to main content

Day: May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of a comprehensive preclinical study assessing SIL204’s therapeutic potential across multiple cancer types beyond pancreatic cancer. The Company is currently finalizing its analysis of the data and expects to announce comprehensive results within the next few days. The now-completed...

Continue reading

IDEX Biometrics ASA: Annual general meeting held on 21 May 2025

IDEX Biometrics ASA held the annual general meeting on 21 May 2025.  All resolutions were passed as proposed in the notice and agenda update for the meeting. The minutes of the meeting will be available at the company’s web site www.idexbiometrics.com in due course. For further information, please contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@idexbiometrics.com About IDEX Biometrics: IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments...

Continue reading

Pet Valu Holdings Ltd. Announces Closing of C$22.5 Million Full Exercise of Over-Allotment Option

Not for distribution to U.S. news wire services or dissemination in the United States. MARKHAM, Ontario, May 21, 2025 (GLOBE NEWSWIRE) — Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, announced today that further to the previously announced closing of the secondary bought deal offering (the “Offering”) of 5,200,000 common shares of the Company (the “Common Shares”) by PV Holdings S.à r.l., Roark Capital Partners II AIV AG, L.P., RCPS Equity Cayman LP and Roark Capital Partners Parallel II AIV AG, L.P. (collectively, the “Selling Shareholders”) at a price of C$28.85 per Common Share, the syndicate of Underwriters (as defined below) have exercised their over-allotment option (the “Over-Allotment Option”) in full and have purchased an additional...

Continue reading

AITX Expands in $50B Security Market as AI Replaces the Security Staff

Company Scales Deployment of Voice-Interactive Devices, Targeting Operational Profitability and Market Leadership Detroit, Michigan, May 21, 2025 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc., (the “Company”) (OTCPK:AITX), a global leader in AI-driven security and productivity solutions, today issued a strategic update spotlighting the Company’s accelerating growth, expanding deployments, and growing influence across the $50 billion security services market1. While many startups continue to speculate about the future of AI, AITX is actively delivering it, with nearly a thousand autonomous devices deployed and a rapidly scaling base of recurring monthly revenue. Earlier this year, AITX reported unaudited fiscal 2025 revenues of $6.13 million, a 275% increase over the prior year. This performance reflects...

Continue reading

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Progress Towards Completion IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update. First Quarter 2025 and Subsequent HighlightsMay 2025: Effected a 1-for-25 reverse stock split of the company’s common stock, which was effective for trading purposes upon the commencement of trading on May 9, 2025. May 2025: Presented pre-clinical data on its proprietary Diabetes Neuromodulation device in a poster presentation at the 12th Annual Minnesota Neuromodulation Symposium. Jonathan J. Waataja, Ph.D., Director of Research...

Continue reading

GCM Grosvenor to Present at the William Blair 45th Annual Growth Stock Conference on June 4, 2025

CHICAGO, May 21, 2025 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, announced today that Michael Sacks, Chairman and Chief Executive Officer of GCM Grosvenor, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4 at 8:40 a.m. CDT.   A link to the live audio webcast of the presentation will be available on GCM Grosvenor’s public shareholders website and the event website. For those unable to listen to the live audio webcast, a replay will be available for 90 days following the presentation.  About GCM Grosvenor  GCM Grosvenor (Nasdaq: GCMG) is a global alternative asset management solutions provider with approximately $82 billion in assets under management across private equity, infrastructure, real estate, credit, and absolute return...

Continue reading

Gabelli U.S. Treasury Money Market Fund Achieves Top Ranking by iMoneyNET™ (EPFR)

RYE, N.Y., May 21, 2025 (GLOBE NEWSWIRE) — Gabelli Funds, LLC is proud to announce that the Gabelli U.S. Treasury Money Market Fund (the “Fund”) (NASDAQ: GABXX) has earned two top honors from iMoneyNet™ (EPFR). The Fund was ranked #1 Money Market Fund in the 100% U.S. Treasury Retail category as of March 31, 2025, and also achieved the highest 12-month total return among 95 funds in the Government Retail category as of April 30, 2025. With $5.6 billion in assets under management, this recognition underscores the Fund’s commitment to a low-cost, tax-efficient strategy focused solely on U.S. Treasury securities, reinforcing its position as a leading choice for investors seeking safety, liquidity, and attractive after-tax returns. Since its launch in 1992, the Gabelli U.S. Treasury Money Market Fund has consistently ranked...

Continue reading

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek’s commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose’s product XHANCE® (fluticasone propionate). “Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty therapeutics company, focused on addressing significant unmet medical needs,” said Evan Loh, MD, Chief Executive Officer of Paratek. “Our medical...

Continue reading

Progressive Reports April 2025 Results

MAYFIELD VILLAGE, OHIO, May 21, 2025 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended April 30, 2025:  April(millions, except per share amounts and ratios; unaudited) 2025   2024   ChangeNet premiums written $ 6,837     $ 6,178     11   %Net premiums earned $ 6,641     $ 5,575     19   %Net income $ 986     $ 421     134   %Per share available to common shareholders $ 1.68     $ 0.72     134   %Total pretax net realized gains (losses) on securities $ (3 )   $ (267 )   (99 ) %Combined ratio   84.9       89.0     (4.1 ) pts.Average diluted equivalent common shares   587.7       587.4     0   %  April 30,(thousands; unaudited) 2025   2024   % ChangePolicies in Force          Personal Lines          Agency – auto 10,246   8,720   18Direct...

Continue reading

Pyxis Tankers Announces Financial Results for the Three Months Ended March 31, 2025

Maroussi, Greece, May 21, 2025 – Pyxis Tankers Inc. (Nasdaq Cap Mkts: PXS), (the “Company”, “we”, “our”, “us” or “Pyxis Tankers”), an international shipping company, today announced unaudited results for the three months ended March 31, 2025. For the three months ended March 31, 2025, our revenues, net, were $9.6 million. For the same period, our time charter equivalent (“TCE”) revenues were $8.4 million, a decrease of $1.8 million, or 17.4%, over the comparable period in 2024. Our net income attributable to common shareholders for the first quarter ended March 31, 2025 was $0.8 million. For the first quarter of 2025, the net income per common share was $0.07 basic and diluted compared to the net income per common share of $0.33 basic and $0.30 diluted for the same period of 2024. Our Adjusted EBITDA for the three months ended March 31,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.